Risk-benefit ratio for TSH- suppressive Levothyroxine therapy in differentiated thyroid cancer

被引：12

作者：

Do Cao, C. ^{[1
]}

Wemeau, J. -L. ^{[1
]}

机构：

[1] CHRU Lille, Serv Endocrinol & Malad Metab, Clin Endocrinol Marc Linquette, F-59037 Lille, France

来源：

ANNALES D ENDOCRINOLOGIE | 2015年 / 76卷

关键词：

Thyroid cancer; Levothyroxine; TSH; Suppressive; Therapy; Adverse effects; RANDOMIZED CONTROLLED-TRIAL; BONE-MINERAL DENSITY; QUALITY-OF-LIFE; STIMULATING HORMONE; THYROTROPIN SUPPRESSION; ATRIAL-FIBRILLATION; CARCINOMA; MANAGEMENT; THYROXINE; DISEASE;

D O I：

10.1016/S0003-4266(16)30014-2

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

In the setting of differentiated thyroid cancer (DTC) management, <0.1 mU/L TSH suppression has been proven to be beneficial for patients likely to have microscopic or macroscopic disease, as TSH has a direct trophic effect on thyroid cancer cells. However, the optimal degree of TSH reduction remains unclear for other categories of DTC patients with better prognosis. Excessive thyroid hormone replacement can lead to atrial fibrillation and osteoporosis. Therefore, levothyroxine dose should be carefully adjusted with respect to underlying individual health status, dynamically reassessed risk of relapse and medical monitoring. Future guidelines should give priority to a tailored approach to TSH suppression therapy in DTC patients. (C) 2015 Published by Elsevier Masson SAS. All rights reserved.

引用

页码：1S47 / 1S52

页数：6

共 38 条

[1] Abonowara A, 2012, CLIN INVEST MED, V35, pE152
[2] [Anonymous], 2014, ICE ENDO C 2014 JUN
[3] Risk for fracture in women with low serum levels of thyroid-stimulating hormone
Bauer, DC
Ettinger, B
Nevitt, MC
Stone, KL
[J]. ANNALS OF INTERNAL MEDICINE, 2001, 134 (07) : 561 - 568
[4] Thyroid hormone use, hyperthyroidism and mortality in older women
Bauer, Douglas C.
Rodondi, Nicolas
Stone, Katie L.
Hillier, Teresa A.
[J]. AMERICAN JOURNAL OF MEDICINE, 2007, 120 (04) : 343 - 349
[5] Impaired cardiac reserve and exercise capacity in patients receiving long-term thyrotropin suppressive therapy with levothyroxine
Biondi, B
Fazio, S
Cuocolo, A
Sabatini, D
Nicolai, E
Lombardi, G
Salvatore, M
Sacca, L
[J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1996, 81 (12) : 4224 - 4228
[6] Benefits of Thyrotropin Suppression Versus the Risks of Adverse Effects in Differentiated Thyroid Cancer
Biondi, Bernadette
Cooper, David S.
[J]. THYROID, 2010, 20 (02) : 135 - 146
[7] Guidelines for the management of differentiated thyroid carcinomas of vesicular origin
Borson-Chazot, F.
Bardet, S.
Bournaud, C.
Conte-Devolx, B.
Corone, C.
D'Herbomez, M.
Henry, J. -F.
Leenhardt, L.
Peix, J. -L.
Schlumberger, M.
Wemeau, J. -L.
Bernard, M. -H.
Calzada-Nocaudie, M.
Caron, P.
Catargi, B.
Chabrier, G.
Charrie, A.
Franc, B.
Hartl, D.
Helal, B.
Kerlan, V.
Kraimps, J. -L.
Leboulleux, S.
Le Clech, G.
Menegaux, F.
Orgiazzi, J.
Perie, S.
Raingeard, I.
Rodien, P.
Rohmer, V.
Sadoul, J. -L.
Schwartz, C.
Tenenbaum, F.
Toubert, M. -E.
Tramalloni, J.
Travagli, J. -P.
Vaudrey, C.
[J]. ANNALES D ENDOCRINOLOGIE, 2008, 69 (06) : 472 - 486
[8] Quality of life and psychometric functionality in patients with differentiated thyroid carcinoma
Botella-Carretero, JI
Galán, JM
Caballero, C
Sancho, J
Escobar-Morreale, HF
[J]. ENDOCRINE-RELATED CANCER, 2003, 10 (04) : 601 - 610
[9] Thyrotropin suppressive therapy in thyroid carcinoma: What are the targets?
Brabant, G.
[J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2008, 93 (04) : 1167 - 1169
[10] Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer
Cooper, David S.
Doherty, Gerard M.
Haugen, Bryan R.
Kloos, Richard T.
Lee, Stephanie L.
Mandel, Susan J.
Mazzaferri, Ernest L.
McIver, Bryan
Pacini, Furio
Schlumberger, Martin
Sherman, Steven I.
Steward, David L.
Tuttle, R. Michael
[J]. THYROID, 2009, 19 (11) : 1167 - 1214

← 1 2 3 4 →